AU2015261775B2 - Novel compounds useful as S100-inhibitors - Google Patents

Novel compounds useful as S100-inhibitors Download PDF

Info

Publication number
AU2015261775B2
AU2015261775B2 AU2015261775A AU2015261775A AU2015261775B2 AU 2015261775 B2 AU2015261775 B2 AU 2015261775B2 AU 2015261775 A AU2015261775 A AU 2015261775A AU 2015261775 A AU2015261775 A AU 2015261775A AU 2015261775 B2 AU2015261775 B2 AU 2015261775B2
Authority
AU
Australia
Prior art keywords
oxo
trifluoromethyl
tetraen
dodeca
triazatricyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015261775A
Other languages
English (en)
Other versions
AU2015261775A1 (en
Inventor
Marie BAINBRIDGE
Stephen EAST
Maria EKBLAD
Jonathan Hargrave
David LIBERG
Natacha Prevost
Ulf Wellmar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of AU2015261775A1 publication Critical patent/AU2015261775A1/en
Application granted granted Critical
Publication of AU2015261775B2 publication Critical patent/AU2015261775B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
AU2015261775A 2014-05-23 2015-05-22 Novel compounds useful as S100-inhibitors Ceased AU2015261775B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169757 2014-05-23
EP14169757.3 2014-05-23
PCT/EP2015/061468 WO2015177367A1 (en) 2014-05-23 2015-05-22 Novel compounds useful as s100-inhibitors

Publications (2)

Publication Number Publication Date
AU2015261775A1 AU2015261775A1 (en) 2016-12-08
AU2015261775B2 true AU2015261775B2 (en) 2019-07-11

Family

ID=50774707

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015261775A Ceased AU2015261775B2 (en) 2014-05-23 2015-05-22 Novel compounds useful as S100-inhibitors

Country Status (12)

Country Link
US (1) US9771372B2 (enExample)
EP (1) EP2991990B1 (enExample)
JP (1) JP6580074B2 (enExample)
KR (1) KR20170005868A (enExample)
CN (1) CN106414448B (enExample)
AU (1) AU2015261775B2 (enExample)
BR (1) BR112016024749A2 (enExample)
CA (1) CA2948436A1 (enExample)
EA (1) EA030604B1 (enExample)
ES (1) ES2620751T3 (enExample)
MX (1) MX2016014483A (enExample)
WO (1) WO2015177367A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019208290A1 (ja) 2018-04-27 2019-10-31 国立大学法人 岡山大学 抗ｓ１００ａ８／ａ９抗体とその用途
US11197908B2 (en) 2018-07-17 2021-12-14 The Board Of Trustees Of The University Of Arkansas Peptoids and methods for attenuating inflammatory response
WO2021085252A1 (ja) 2019-10-30 2021-05-06 国立大学法人 岡山大学 炎症性肺疾患の予防及び／又は治療剤
WO2023209141A1 (en) 2022-04-29 2023-11-02 Westfälische Wilhelms-Universität Münster Benzo[d]imidazo[1,2-a]imidazoles and their use in diagnosis
WO2025132458A1 (en) 2023-12-18 2025-06-26 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069965A1 (en) * 2001-03-05 2002-09-12 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
EP1986009A1 (en) * 2007-04-26 2008-10-29 Active Biotech AB Screening method
US20090186879A1 (en) * 2008-01-22 2009-07-23 Takeda Pharmaceutical Company Limited Tricyclic compounds and use thereof
CN101597262A (zh) * 2002-03-05 2009-12-09 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
WO2015086525A1 (en) * 2013-12-09 2015-06-18 Ucb Biopharma Sprl Fused tricyclic benzimidazoles derivatives as modulators of tnf activity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
IL154107A0 (en) 2000-07-26 2003-07-31 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
GB0117506D0 (en) 2001-07-18 2001-09-12 Bayer Ag Imidazopyridinones
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
JP2010504980A (ja) 2006-09-28 2010-02-18 エグゼリクシス， インコーポレイテッド Ｊａｋ−２モジュレーターおよび使用方法
EP2132207A2 (en) 2007-03-23 2009-12-16 Amgen Inc. Heterocyclic compounds and their uses
EP2170072A4 (en) 2007-06-13 2010-10-27 Glaxosmithkline Llc Farnesoid X RECEPTOR AGONISTS
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
CN102414180A (zh) 2009-03-02 2012-04-11 西特里斯药业公司 作为沉默调节蛋白调节剂的8-取代的喹啉及相关的类似物
KR20140096100A (ko) 2011-11-03 2014-08-04 에프. 호프만-라 로슈 아게 이환 피페라진 화합물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069965A1 (en) * 2001-03-05 2002-09-12 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
CN101597262A (zh) * 2002-03-05 2009-12-09 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
EP1986009A1 (en) * 2007-04-26 2008-10-29 Active Biotech AB Screening method
US20090186879A1 (en) * 2008-01-22 2009-07-23 Takeda Pharmaceutical Company Limited Tricyclic compounds and use thereof
CN101981031A (zh) * 2008-01-22 2011-02-23 武田药品工业株式会社 具有促肾上腺皮质激素释放因子拮抗活性的三环化合物和含有它们的药物组合物
WO2015086525A1 (en) * 2013-12-09 2015-06-18 Ucb Biopharma Sprl Fused tricyclic benzimidazoles derivatives as modulators of tnf activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. DESCOURS ET. AL., SYNTHESIS, (1983-12-01), no. 12, pages 1033 - 1036 *
F. TROXLER ET. AL., HELVETICA CHIMICA ACTA, (1974-08-01), vol. 57, no. 8, pages 2356 - 2364 *
Franz Troxler et al., "Synthese von Pyrimido[1,2-a]benzimidazolen durch Umsetzung von 2-aminobenzimidazol mit Acetylendicarbonsaure-dimethylester und ihre Uberfuhrung in Imidazo[l,2-a]benzimidazole", HELVETICA CHIMICA ACTA *
I. MESSINA ET. AL., "Solid-Phase Synthesis of 5-Noranagleride Derivatives.", ACS COMBINATORIAL SCIENCE, (2013-12-04), vol. 16, pages 33 - 38 *

Also Published As

Publication number Publication date
HK1221463A1 (en) 2017-06-02
EP2991990B1 (en) 2017-02-01
EA030604B1 (ru) 2018-08-31
US20170204098A1 (en) 2017-07-20
CA2948436A1 (en) 2015-11-26
MX2016014483A (es) 2017-01-23
WO2015177367A1 (en) 2015-11-26
JP6580074B2 (ja) 2019-09-25
JP2017516772A (ja) 2017-06-22
CN106414448A (zh) 2017-02-15
EP2991990A1 (en) 2016-03-09
CN106414448B (zh) 2019-04-19
US9771372B2 (en) 2017-09-26
BR112016024749A2 (pt) 2017-08-15
AU2015261775A1 (en) 2016-12-08
KR20170005868A (ko) 2017-01-16
EA201692405A1 (ru) 2017-06-30
ES2620751T3 (es) 2017-06-29

Similar Documents

Publication Publication Date Title
JP7033764B2 (ja) Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体
JP7321194B2 (ja) セレブロン（ｃｒｂｎ）に対するリガンド
CN108290879B (zh) 用作irak抑制剂的杂芳基化合物及其用途
AU2022265301B2 (en) Compounds and their uses as cd38 inhibitors
JP7577655B2 (ja) 環状尿素
AU2015261775B2 (en) Novel compounds useful as S100-inhibitors
KR20130133051A (ko) 6,5-헤테로사이클릭 프로파길릭 알콜 화합물 및 이의 용도
AU2016214492B2 (en) 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity
JP2018506571A (ja) Ｒｈｏ関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
JP7064495B2 (ja) ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体
EP3481824B1 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
US10385069B2 (en) Imidazo[2,1-B]thiazole and 5,6-dihydroimidazo[2,1-B]thiazole derivatives useful as S100-inhibitors
CN112574176A (zh) 一种杂芳基类化合物及其应用
JP2023551272A (ja) ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途
HK1221463B (en) Novel compounds useful as s100-inhibitors
BR122023020299A2 (pt) Composto, uso de um composto, composição farmacêutica e processo para preparação de um composto
MX2008009811A (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
HK1155440A (en) Inhibitors of phosphatidylinositol 3-kinase

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired